

eTable 1. CAR T cells therapies in patient with and without ICANS[¥]

| | Total (N=38) | Patients without ICANS (N=21) | Patients with ICANS (N=17) | P value |
|---|--------------|-------------------------------|----------------------------|---------|
| CD19-CAR constructs | | | | 0.1 |
| Coreceptor CD28 | 26 (68%) | 12 (57%) | 14 (82%) | |
| Coreceptor 4-1BB | 12 (32%) | 9 (43%) | 3 (18%) | |
| AXICABTAGENE CIROLEUCEL (CD28) | 21 (55%) | 9 (43%) | 12 (71%) | 0.3 |
| BREXUCABTAGENE AUTOLEUCEL (CD28) | 5 (13%) | 3 (14%) | 2 (12%) | |
| LISOCABTAGENE MARALEUCEL (4-1BB) | 7 (18%) | 6 (29%) | 1 (5.9%) | |
| TISAGENCLEUCEL (4-1BB) | 5 (13%) | 3 (14%) | 2 (12%) | |

¥ ICANS: Immune effector cell-associated neurotoxicity syndrome